(Credit-Canva)
The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.
Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.
Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.
Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.
Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.
Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.
Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.
According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.
All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.
Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.
Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.
Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.
People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.
Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.
Credit: AI
A new safety analysis has found that Wegovy, the recently launched blockbuster weight loss medication containing semaglutide, may cause a rare but dangerous eye condition that can lead to sudden and permanent vision loss.
The analysis, published in the British Journal of Ophthalmology, compared Wegovy, semaglutide tablets and other GLP-1 drugs like Ozempic by examining more than 30 million reports from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) submitted between 2017 and 2024.
Scientists found a safety signal that linked semaglutide medicines to non-arteritic anterior ischemic optic neuropathy (NAION), also known as eye stroke.
The signal appeared to be nearly five times stronger for Wegovy than for Ozempic, despite both medicines containing the same active ingredient, semaglutide.
NAION occurs when blood flow to the optic nerve suddenly gets reduced, causing damage to the nerve responsible for transmitting visual information from the eye to the brain. The patient experiences painless vision loss in one eye.
While some patients experience partial improvement, the vision loss is frequently permanent. There is currently no proven treatment to reverse the damage.
Researchers state that the findings do not prove that Wegovy causes NAION. Instead, they observe a typical signal, meaning an unexpected pattern observed in a large safety database that requires immediate further investigation.
Such pharmacological analyses are useful for identifying rare and adverse side effects that may not emerge during clinical trials.
Also read: Novo Nordisk Launches Awiqli In India: All About The World's First Once-Weekly Insulin
The stronger link observed with Wegovy and NAION compared with Ozempic has also raised new questions. Both drugs contain semaglutide, but Wegovy is prescribed at higher doses for obesity, while Ozempic is used to treat type 2 diabetes.
Researchers say that factors such as higher dosing, differences in patient populations, or underlying health conditions could help explain the disparity, although more research is needed.
The latest findings build on growing scientific interest in the potential eye-related risks of GLP-1 receptor agonists.
Previous observational studies have also reported an increased risk of NAION among semaglutide users, prompting regulators in Europe to add the condition as a very rare side effect to semaglutide product information last year.
Health experts emphasize that patients should not stop taking Wegovy without consulting their healthcare provider. For most users, the drug's benefits in managing obesity and reducing associated health risks are likely to outweigh the extremely rare risk of developing NAION.
However, anyone taking Wegovy who experiences sudden blurred vision or loss of vision should seek immediate medical attention.
The GLP-1 medication industry is in a boom. Novo Nordisk, the maker of GLP-1 medicines like Ozempic and Wegovy, is currently exploring a new way to deliver weight-loss treatment that could reduce the need for weekly injections.
The implant, known as NPM-139, is a miniature device developed using Vivani Medical's proprietary NanoPortal technology. Rather than requiring patients to inject semaglutide every week, the tiny implant is placed beneath the skin and slowly releases the medication over an extended period.
If successful, it could mark a significant step toward making GLP-1 drug more convenient for people living with obesity.
Credit: iStock
COVID-19 infections have resurfaced in India, with Andhra Pradesh reporting two deaths and several active cases, prompting health authorities to step up surveillance and preparedness measures.
A 52-year-old man from Kadapa's Rajampet area, who tested positive for COVID-19 after developing fever and cough, died while undergoing treatment at Christian Medical College (CMC), Vellore.
In another case, a 43-year-old man from Kadapa, who was admitted to the Government General Hospital with health complications, tested positive and later died while receiving treatment in the COVID-19 Intensive Care Unit.
A 25-year-old medical student from Kadapa Medical College has also tested positive for the virus and is currently undergoing treatment through home isolation. Several more cases have also been reported.
Doctors say they have seen a rise in COVID-19 cases over the past few weeks.
Dr. Lancelot Pinto, Consultant Pulmonologist and Epidemiologist at the PD Hinduja Hospital, Mumbai, told HealthandMe that SARS-CoV-2 has frequently been detected in patients presenting with viral respiratory infections.
"So when we send throat swabs in the context of a viral respiratory infection, we have detected SARS-CoV-2 as the causative organism often. It doesn't seem that this is a more virulent strain based on our experience so far. But in those who are immunocompromised, who are vulnerable because of their health risks, it can cause severe disease."
While the exact variant behind these cases has not yet been confirmed and samples have been sent for genome sequencing, experts say the virus currently circulating in India is largely made up of Omicron sub-lineages.
"The virus currently circulating in India is largely made up of Omicron sub-lineages, which generally cause milder illness than earlier variants, though they remain highly transmissible," Dr. Neha Rastogi, Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurugram, told HealthandMe.
According to Dr. Pinto, viruses are capable of triggering what is known as an inflammatory cascade—a strong immune response that can sometimes contribute to severe illness.
"This cascade is such that there's a strong immune response to the virus that can sometimes be detrimental to humans, causing severe disease. We also know that any viral infection, however innocuous it may seem, has the potential of increasing your cardiovascular risk."
He explained that viral infections can also increase cardiovascular risk, meaning people already at risk of heart-related complications may experience poorer outcomes.
"And therefore, those who are at an increased risk of cardiovascular events could suffer from poor outcomes in the context of any viral infections."
Another concern, he said, is the limited availability of antiviral medicines.
"What has been concerning, though, is the difficulty of procuring antivirals at present. So drugs such as remdesivir and paxlovid are not easily available. And therefore, we are not able to offer it to vulnerable and high-risk individuals. And I hope this gets fixed in the near future."
Although the circulating Omicron sub-lineages generally cause milder illness, they can still lead to severe disease in vulnerable individuals.
Those most at risk include:
Despite the lower overall severity of the current variants, health experts say vigilance remains important. To reduce the risk of infection, people should stay up to date with COVID-19 vaccinations, wear masks in crowded indoor settings, maintain hand hygiene, ensure good ventilation, and avoid close contact when unwell.
Anyone experiencing symptoms such as fever, cough, or breathlessness should get tested and seek timely medical advice.
"If you are a high-risk individual and suffer from diseases such as diabetes, high blood pressure, chronic kidney disease, chronic liver disease, or respiratory disease such as COPD, this is the time to be a little cautious about exposing yourself to those who are ill, trying and avoiding crowds, trying and avoiding places where there's a conglomeration of individuals together and easy to pick up viruses. Mask up with a high-efficiency mask if it's feasible, especially if you are exposed to such kind of situations," Dr Pinto said.
For people without these underlying conditions, he said the virus appears to behave much like other seasonal respiratory viruses.
"For the average person who does not have a high risk in terms of these comorbidities, it does appear that this virus behaves just like any other seasonal influenza virus or any other seasonal virus."
Credit: iStock
Europe's record-breaking June heatwave led to an estimated 10,000 excess deaths across 27 countries, with older adults accounting for the overwhelming majority of fatalities, according to official data.
Data published by EuroMOMO—a mortality monitoring network supported by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO)—showed around 10,000 excess deaths during the week of June 22-28, when extreme heat peaked across France, Spain, Britain and several other European countries.
More than 9,000 of these deaths were among people aged 65 years and older.
"To have this kind of excess at this time of year is unusual. It's really high," Lasse Vestergaard, Chief Physician at Denmark's Statens Serum Institut, which hosts EuroMOMO, was quoted as saying to Reuters news agency.
"It is difficult to explain this high excess mortality by anything but the extreme heat," he added.
The figures are based on all-cause mortality, meaning they include deaths from all causes rather than only those officially classified as heat-related.
Scientists have also said the late-June heatwave would have been "virtually impossible" without human-caused climate change, which is making extreme heat events more frequent and intense.
A separate analysis by researchers from the London School of Hygiene & Tropical Medicine (LSHTM), Imperial College London, and the Met Office estimated more than 2,700 excess heat-related deaths during the May and June 2026 heatwaves in England and Wales.
Researchers estimated:
The study found that around 42% of the total heat-related deaths across both heatwaves were attributable to human-caused climate change.
According to the report, climate change increased daytime maximum temperatures across England and Wales by 3°C to 4°C.
The analysis estimated that climate change was responsible for:
Both heatwaves shattered long-standing temperature records, with 35.1°C recorded in West London in May and 37°C in East Anglia in June.
"We are still in the first half of summer in the UK and large parts of England and Wales have already experienced two record-breaking heatwaves," said Dr Malcolm Mistry, Assistant Professor in Climate and Geo-spatial Modelling at LSHTM.
According to the Copernicus Climate Change Service (C3S), June 2026 was the hottest June ever recorded in western Europe and the second warmest globally.
The record temperatures were driven in part by the highest sea surface temperatures ever recorded for June.
"Heatwaves like this are what we expect to see in a changing climate," said John Kennedy, Head of Climate Information at the World Meteorological Organization (WMO).
He noted that Europe has warmed by around 2°C over the past 50 years, making it the world's fastest-warming continent and increasing the frequency of extreme heat events.
Extreme heat is often called the "silent killer" because heat-related deaths are frequently underreported. Globally, an estimated 489,000 people died from heat-related causes each year between 2000 and 2019, according to modeled estimates.
Heat stress develops when the body absorbs more heat than it can release. While sweating and increased blood flow to the skin normally help regulate body temperature, these cooling mechanisms become less effective during prolonged periods of intense heat—especially when humidity is high.
According to Lachlan McIver, Health Advisor at the WHO-WMO Climate and Health Joint Office, older adults, infants, pregnant women, outdoor workers, people experiencing homelessness, and those with chronic illnesses are at the greatest risk, although prolonged extreme heat can affect anyone.
© 2024 Bennett, Coleman & Company Limited